Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 137

1.

Disturbed postprandial glucose metabolism and gut hormone responses in non-diabetic patients with psoriasis.

Gyldenløve M, Vilsbøll T, Holst JJ, Zachariae C, Skov L, Knop FK.

Br J Dermatol. 2015 Mar 27. doi: 10.1111/bjd.13789. [Epub ahead of print]

PMID:
25819574
2.

Fixed combination of insulin and a glucagon-like peptide-1 analog for the treatment of type 2 diabetes, exemplified by insulin degludec and liraglutide.

Vedtofte L, Knop FK, Vilsbøll T.

Expert Rev Clin Pharmacol. 2015 Mar 30:1-10. [Epub ahead of print]

PMID:
25816888
3.

Recovery of the Incretin Effect in Type 2 Diabetic Patients After Biliopancreatic Diversion.

Novaes FS, Vasques AC, Pareja JC, Knop FK, Tura A, Chaim ÉA, Geloneze B.

J Clin Endocrinol Metab. 2015 Mar 5:jc20144042. [Epub ahead of print]

PMID:
25742514
4.

Effects of sitagliptin on counter-regulatory and incretin hormones during acute hypoglycaemia in patients with type 1 diabetes: a randomized double-blind placebo-controlled crossover study.

Schopman JE, Hoekstra JB, Frier BM, Ackermans MT, de Sonnaville JJ, Stades AM, Zwertbroek R, Hartmann B, Holst JJ, Knop FK, Holleman F.

Diabetes Obes Metab. 2015 Feb 19. doi: 10.1111/dom.12453. [Epub ahead of print]

PMID:
25694217
5.

Patients with psoriasis are insulin resistant.

Gyldenløve M, Storgaard H, Holst JJ, Vilsbøll T, Knop FK, Skov L.

J Am Acad Dermatol. 2015 Apr;72(4):599-605. doi: 10.1016/j.jaad.2015.01.004. Epub 2015 Feb 1.

PMID:
25653028
6.

A 25-year-old woman with type 2 diabetes and liver disease.

Junker AE, Gluud LL, Pedersen J, Langhoff JL, Holst JJ, Knop FK, Vilsbøll T.

Case Rep Gastroenterol. 2014 Dec 12;8(3):398-403. doi: 10.1159/000369968. eCollection 2014 Sep-Dec.

8.

Adverse drug reactions associated with the use of liraglutide in patients with type 2 diabetes--focus on pancreatitis and pancreas cancer.

Chalmer T, Almdal TP, Vilsbøll T, Knop FK.

Expert Opin Drug Saf. 2015 Jan;14(1):171-80. doi: 10.1517/14740338.2015.975205. Epub 2014 Nov 3.

PMID:
25363438
9.

Glucagon and type 2 diabetes: the return of the alpha cell.

Lund A, Bagger JI, Christensen M, Knop FK, Vilsbøll T.

Curr Diab Rep. 2014 Dec;14(12):555. doi: 10.1007/s11892-014-0555-4.

PMID:
25344790
10.

Clearance of glucoregulatory peptide hormones during haemodialysis and haemodiafiltration in non-diabetic end-stage renal disease patients.

Jørgensen MB, Idorn T, Knop FK, Holst JJ, Hornum M, Feldt-Rasmussen B.

Nephrol Dial Transplant. 2015 Mar;30(3):513-20. doi: 10.1093/ndt/gfu327. Epub 2014 Oct 15.

PMID:
25319937
11.

Glucometabolic hormones and cardiovascular risk markers in antipsychotic-treated patients.

Ebdrup BH, Knop FK, Madsen A, Mortensen HB, Søgaard B, Holst JJ, Szecsi PB, Lublin H.

J Clin Psychiatry. 2014 Sep;75(9):e899-905. doi: 10.4088/JCP.13m08820.

12.

[Duodenal-jejunal bypass sleeve - a potential alternative to bariatric surgery?]

Rohde U, Gylvin S, Vilmann P, Friis SU, Langholz E, Vilsbøll T, Knop FK.

Ugeskr Laeger. 2014 Sep 8;176(37). pii: V01140053. Danish.

PMID:
25294038
13.

On the role of gallbladder emptying and incretin hormones for nutrient-mediated TSH suppression in patients with type 2 diabetes.

Sonne DP, Lund A, Faber J, Holst JJ, Vilsbøll T, Knop FK.

Endocr Connect. 2014 Dec;3(4):193-9. doi: 10.1530/EC-14-0088. Epub 2014 Oct 2.

15.

Glucose-dependent insulinotropic polypeptide inhibits bone resorption in humans.

Nissen A, Christensen M, Knop FK, Vilsbøll T, Holst JJ, Hartmann B.

J Clin Endocrinol Metab. 2014 Nov;99(11):E2325-9. doi: 10.1210/jc.2014-2547. Epub 2014 Aug 21.

PMID:
25144635
16.

Lack of effect of the glucagon-like peptide-1 receptor agonist liraglutide on psoriasis in glucose-tolerant patients--a randomized placebo-controlled trial.

Faurschou A, Gyldenløve M, Rohde U, Thyssen JP, Zachariae C, Skov L, Knop FK, Vilsbøll T.

J Eur Acad Dermatol Venereol. 2015 Mar;29(3):555-9. doi: 10.1111/jdv.12629. Epub 2014 Aug 20.

PMID:
25139195
17.

The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus.

Christensen M, Miossec P, Larsen BD, Werner U, Knop FK.

Expert Opin Drug Discov. 2014 Oct;9(10):1223-51. doi: 10.1517/17460441.2014.942638. Epub 2014 Aug 14.

PMID:
25119443
18.

Glucose-dependent insulinotropic polypeptide augments glucagon responses to hypoglycemia in type 1 diabetes.

Christensen M, Calanna S, Sparre-Ulrich AH, Kristensen PL, Rosenkilde MM, Faber J, Purrello F, van Hall G, Holst JJ, Vilsbøll T, Knop FK.

Diabetes. 2015 Jan;64(1):72-8. doi: 10.2337/db14-0440. Epub 2014 Jul 22.

PMID:
25053587
19.

Sevelamer in a diabetologist's perspective: a phosphate-binding resin with glucose-lowering potential.

Brønden A, Hansen M, Sonne DP, Rohde U, Vilsbøll T, Knop FK.

Diabetes Obes Metab. 2015 Feb;17(2):116-20. doi: 10.1111/dom.12355. Epub 2014 Jul 31.

PMID:
25041567
20.

Specificity and sensitivity of commercially available assays for glucagon-like peptide-1 (GLP-1): implications for GLP-1 measurements in clinical studies.

Bak MJ, Wewer Albrechtsen NJ, Pedersen J, Knop FK, Vilsbøll T, Jørgensen NB, Hartmann B, Deacon CF, Dragsted LO, Holst JJ.

Diabetes Obes Metab. 2014 Nov;16(11):1155-64. doi: 10.1111/dom.12352. Epub 2014 Jul 22.

PMID:
25041349
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk